Background: Nonavalent (9v) human papilloma virus vaccine targets high-risk human papillomavirus (HR-HPV) types 16, 18, 31, 33, 45, 52, 58, and low-risk 6, 11. We examined prevalence, incidence, and clearance of anal and cervical HR-HPV in HIVinfected women.
Persons with human immunodeficiency virus (HIV) infection are living longer owing to effective combination antiretroviral therapy (ART), and non-acquired immune deficiency syndrome (non-AIDS)-defining conditions, including cancers, are increasingly diagnosed among them [1] . Despite the immunologic reconstitution associated with ART, the prevalence of anogenital human papillomavirus (HPV) infections and associated diseases remains high [1] [2] [3] [4] . Persistent infection with high-risk HPV causes squamous dysplasia and cancer of the cervix, and 40%-90% of anal, vulvar, vaginal, penile, and oropharyngeal cancers [5, 6] . Of the estimated 14 million new cancers occurring in 2012 worldwide, almost 5% were attributable to HPV infection [7] .
Anogenital HPV infection is multicentric, and anal HPV infection may be a reservoir causing cervical infection and vice versa [8, 9] . Several studies have shown that, among HIVinfected women, prevalence of anal HPV infection is greater than that of cervical infection [8] [9] [10] [11] [12] , and HPV-infected women are at higher risk for HPV-associated cancers than HIVuninfected women [13] . The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) showed a significant, increasing trend in incidence of anal cancer of 6% per year in HIV-infected persons. The incidence of anal cancer among HIV-infected women ranged from 3.9 to 30 per 100 000 women [4, 12] .
While secondary cervical cancer prevention strategies, such as cytology and HPV testing, have successfully reduced cervical cancer incidence, there is no current consensus on anal cancer prevention methods among women. Over the last few years, focus has been placed on implementing primary preventive strategies, specifically vaccine development. There are 3 HPV vaccines licensed in the United States, although currently only the nonavalent vaccine is available. The quadrivalent HPV vaccine Gardasil (Merck & Co., Inc.) was approved in June 2006 to prevent infection due to HPV types 6, 11, 16, and 18. The bivalent HPV vaccine Cervarix (GlaxoSmithKline) was approved in October 2009 to prevent infection due to HPV types 16 and 18. In December 2014, a nonavalent HPV vaccine, Gardasil 9, was approved for prevention of infection with the 4 HPV types in the quadrivalent vaccine and an additional 5 highrisk (HR) HPV types, 31, 33, 45, 52, and 58 (9v-HPV; Merck & Co., Inc.), increasing type-specific protection from 70% up to 90% of HPV types that cause cervical cancer [14, 15] . The quadrivalent HPV vaccine is safe and immunogenic in HIV-infected persons [16, 17] , and the 9v vaccine has been shown to have comparable immunogenicity rates to the quadrivalent vaccine for the 4 types found in both vaccines [18] .
We examined the prevalence, incidence, and clearance of the 7 HR-HPV types covered by the nonavalent vaccine (9v HR-HPV; HPV 16, 18, 31, 33, 45, 52, 58) , and the 7 HR-HPV types not covered (non-9v HR-HPV; HPV 35, 39, 51, 56, 59, 66, 68), in HIV-infected women in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study).
METHODS

Study Design and Population
From March 2004 through June 2006, the SUN Study enrolled 700 HIV-infected adults, including 167 women, from 7 clinics in 4 US cities, into a prospective observational cohort study. Data on anal and cervical HPV infection and cytology were available for 126 of 167 women. The study design, and data collection and management methods, have been described previously [19] . Participants were generally healthy, HIV-infected patients receiving routine outpatient care, who were either antiretroviral (ARV)-naive or whose antiretroviral experience consisted only of effective combination ART. Patient data were abstracted from medical charts, entered into an electronic database (Clinical Practice Analyst; Cerner Corporation, Vienna, VA) by trained staff, reviewed for quality, and analyzed centrally. Additional data were collected through physical examination, noninvasive imaging, testing for sexually transmitted infections (syphilis, trichomonas, and oral, rectal, and urine gonococcal and chlamydial infections), and an audio computer-assisted self-interview (ACASI). Cervical and anal samples for cytology, and HPV detection and genotyping, were collected at baseline and annually. The study protocol was approved and reviewed annually by the institutional review boards of the Centers for Disease Control and Prevention (CDC) and each participating site.
Anal and Cervical Sample Collection and Examination
Sample collection, processing, and HPV testing have been described previously [3] . Two anal swabs were collected, the first placed into PreservCyt collection medium for preparation of a ThinPrep slide (Marlborough, MA) for cytology, and the second into Digene Specimen Transport Medium (STM, Qiagen Incorporated, Valencia, CA) for HPV testing. Cervical cytology specimens were collected, per study clinic protocol as part of each participant's routine care; only data from samples collected within 90 days of the appropriate visit were included. Cervical HPV specimens for detection and genotyping were obtained using a cytobroom or cytobrush, and transferred into PreservCyt collection medium (Hologic Incorporated, Marlborough, MA, www.thinprep.com) and were only done as part of the study.
All cytologic results were classified according to the Bethesda System terminology [20] . We defined abnormal cytology as the presence of atypical squamous cells (ASC-US or ASC-H), lowgrade squamous intraepithelial lesions (LSIL), or high-grade intraepithelial lesions (HSIL). Anal cytology specimens were evaluated by a single pathologist with expertise in the interpretation of anal cytology (T.M. Darragh). Cervical cytology specimens were evaluated per local protocol. Women with abnormal cytology were referred to care per prevailing guidelines for anogenital cancer prevention. Anal and cervical STM samples for HPV detection were stored at 4°C and mailed weekly at ambient temperature to CDC, and stored at −4°C until DNA was extracted from 150 μL using a Roche MagNA Pure automated extractor with external lysis and DNA isolation kit III (Roche Diagnostics, Indianapolis, IN). The 100-μL extract was stored at −20°C.
HPV Detection and Typing
The Roche HPV Linear Array research-use-only kit (Roche Diagnostics) was used following the manufacturer's protocol, except that 10 μL of extract was used in the 100 μL reaction, and hybridization and detection was automated. The assay used L1 consensus polymerase chain reaction (PCR) with biotinylated primers and type-specific hybridization detecting 37 different HPV types ( ) and an endogenous control gene (β-globin). Each assay batch included controls for extraction and PCR contamination, and a low-copy positive control (50 copies) for HPV 16. Results for HPV type 52 may have been ambiguous because of cross-hybridization of the HPV type 52 probe with types 33, 35, and 58. To unambiguously determine the presence of type 52 in samples with any combination of the 3 other types, an HPV type-52-specific realtime PCR assay was used [21] .
Statistical Methods
Statistical analysis was performed using SAS, version 9.3 (SAS Institute, Inc., Cary, NC). We defined incident infection as detection of a HR-HPV type not found at baseline, and clearance as 2 consecutive visits when the respective HPV type was not detected. Overall clearance was determined by the percentage of women who cleared all prevalent HPV types from an anatomic site, while individual rates were the clearance of each individual type. We calculated incidence rates per 100 person-years with associated 95% confidence intervals (CI). We used McNemar's test for correlated proportions to assess differences in the detection of HPV, and the various types of HPV, identified from paired anal and cervical specimens from the baseline visit.
Ethical Considerations
The investigation followed the guidelines of the United States Department of Health and Human Services regarding protection of human subjects. The study protocol was approved and renewed annually by each participating institutions' ethical review board. All study participants provided written, informed consent.
RESULTS
We included data from 126 (75%) of the 167 female SUN Study participants; median follow-up was 59.4 months with a total of 472 person-years of follow up. The remainder were excluded due to history of hysterectomy (n = 21), unsatisfactory HPV or cytology sample from either the anus or cervix (n = 17, 10 missing both anal and cervical data; 3 cervical only; and 4 anal only), or incomplete ACASI data (n = 3). The excluded women had similar HPV prevalences and demographics. At baseline, among the 126 women (median age 38 years), 57% were non-Hispanic black, 32% non-Hispanic white, 11% Hispanic or other race/ethnicity, and 52% current cigarette smokers. Thirteen percent were ARV-naive, 67% had a plasma HIV RNA viral load < 400 copies/ mL, and median enrollment and nadir CD4 cell counts were 402 and 203 cells/mm 3 , respectively. Thirty-six percent reported no sexual partners in the 6 months prior to enrollment, and only 2% reported having ≥4 sexual partners during the same period; 40% reported ever having anal sex (Table 1 ) [19] .
HPV Prevalence
As seen in our initial prevalence analysis [3] , baseline HPV infection was more prevalent at the anus (90%) than the cervix (83%) (P = .088), including infection with both HR (79% vs 61%, respectively, P < .001) and other (81% vs 63%, respectively, P < .001) HPV types ( Table 2 ). The prevalence did not differ significantly between women in different age groups, with different nadir or current CD4 cell counts, by number of sexual partners, or by anal sex [3] .
The prevalence of 9v HR-HPV types was likewise higher in the anus than the cervix: 67% versus 51% (P = .002) and non-9v HPV types 54% and 29% (P < .001), respectively. Of the 9v types, HPV 16 (25%) and 45 (23%) were the most common types detected in the anus, whereas 16 (19%) and 58 (14%) were most common in the cervix. The most prevalent non-9v types were HPV 35 (19%) and 51 (17%) in the anus, and 39 (9%) and 66 (8%) in the cervix. The prevalence of each individual HR-HPV type is shown in Tables 2 and 3. At baseline, 31 women (25%) had no 9v HR-HPV types in either anus or cervix; 42 (33%) had 1 or more 9v type in either only the anus or only the cervix, and 53 (42%) had 9v types in both anatomical areas concurrently (Table 4 ). During 5 years of follow-up, the annual point prevalence of anal 9v HR-HPV types was 43%-58%, and cervical 27%-38%, and for non-9v HR-HPV types, 28%-45% and 11%-23%, respectively (Figure 1 ).
HPV Incidence
In the anus and cervix, overall incidence rates for a new HR-HPV type infection, including 9v and non-9v, were 15.4 and 14.4 per 100 person-years, respectively. Both 9v and non-9v incidence rates were similar (9v: 10.4 vs 9.5 per 100 person-years) and (non-9v: 8.5 vs 8.3 per 100 person-years), (13) HIV RNA viral load < 400 copies/mL, n (%) 85 ( at the anus and cervix, respectively (Table 3) . Incidence rates for individual HR-HPV types did not differ significantly by anatomical site. Additionally, incidence rates specifically for HPV 16 or 18 did not differ (4.0 and 3.0 per 100 person-years, respectively).
HPV Clearance
Overall clearance of any anal HR-HPV type was 71%, and cervical HR-HPV type, 89%. Clearance rates for both 9v and non-9v types were generally lower in the anus compared with the cervix (Table 3) . Clearance of any anal 9v HR-HPV types was 42%, compared with cervical, 61%. Clearance rates for anal non-9v HR-HPV were 46%, and cervical 59%. (Table 3 ). Though small numbers limited analyses of clearance of 1 HR type compared with 2 or more, for both 9v and non-9v HR-HPV, women having 2 or more types were less likely to clear HPV compared with those having only 1 type, both in the anus and in the cervix (Table 3) . 
Anal and Cervical Cytology
During 5 years of follow-up, 5 women had no anal and 3 had no cervical cytology collected; the median number collected from each site was 4 (anal interquartile range [IQR] 3-5, cervical IQR 2-6). An abnormality was detected in 141 (29%) anal and 127 (26%) cervical cytologies; 63 (13%) women had both. The majority of HR-HPV types detected in both anal and cervical cytological abnormalities had both 9v and non-9v HR-HPV types, or 9v types, only; 8% of abnormal anal and 12% of abnormal cervical cytologies had no 9v HR-HPV. Specifically, most women with HSIL/ASC-H, about two-thirds, also had concurrent 9v and non-9v HPV infections (Figure 2 ).
DISCUSSION
In our ethnically diverse population of HIV-infected women, the prevalence of anal HR-HPV infection was higher than cervical [3] , and for most HPV types, cleared more slowly. The prevalence of anal and cervical HR-HPV infection in our cohort is consistent with, or even higher than, prevalence estimates reported in other studies of HIV-infected women from different geographic areas [8, 12, 22] . Our data are consistent with other studies where HPV infection differs between anatomical compartments, possibly due to local mucosal environment, different sexual behaviors and transmission, or efficacy of the immune response to clear infection [8, 23] . As previously reported, history of anal sex was not associated with HPV prevalence [3] . Overall, the prevalence of cervical 9v HR-HPV types was much higher in our HIV-infected cohort, 51% compared with 14.1%, among a nationally representative sample of women in the National Health and Nutrition Examination Survey [24] . Although the prevalence of HR-HPV types included in the vaccine was higher in both the anus and cervix as compared with non-9v HR-HPV types, the prevalence of non-9v types was still substantial: 54% and 29% in anus and cervix, respectively. Furthermore, 23% of women in our cohort had a non-9v HR-HPV in the anus and the cervix, concurrently. The most common anal non-9v type was HPV 35, and cervical HPV 39. The incidence rates of HR-HPV types were similar in the anus and cervix, both for 9v and non-9v types. Few studies have reported incidence rates among HIV-infected women; even fewer have compared rates at the anus and cervix. Incidence rates of anal and cervical HPV 16 were lower in our study than other published studies of HIV-infected persons. In a prospective study including 153 women, 168 men who have sex with men (MSM), and 69 men who have sex with women (MSW), anal HPV 16 incidence rates were 8.28 per 100 person-years (6.9 per 1000 person-months) [23] compared with 2.8 per 100 person-years in our cohort. A more recent study of 215 HIVinfected and uninfected women from India likewise showed higher rates of cervical HPV 16 and 58 infection (2.51 and 2.75 per 100 person-years, respectively) compared with 1.8 and 1.0 per 100 person-years in our cohort, although rates of other types were lower [25] . Among HIV-infected men, incidence of anal HPV 16 infection was 3.5 per 100 person-years [26] compared with 2.8 per 100 person-years in our female cohort. These differences likely reflect variation in sexual behaviors and demographics among the study populations, and varying geographic distributions of individual HPV types [24, 27] . In the HPV Infection in Men (HIM) cohort of HIV-uninfected men, lower rates of incident anal HPV infections were observed with advancing age, except rates of 9v HPV-type infections, which remained constant across the lifespan [28] .
We report a HR-HPV clearance rate of 71% and 89% in anus and cervix, respectively. Clearance rates were lower in the anus than the cervix for most HR-HPV types. Anal and cervical 9v HR-HPV types had similar clearance rates compared with non-9v HR-HPV types. There are limited data about HPV clearance rates in HIV-infected women, and definitions of clearance, and HPV types included in the analyses, differ and therefore cannot be readily compared with our data [25, 29] . Among an HIV-uninfected Hawaiian cohort of 1363 women, 69% of HR-HPV infections cleared within 1 year [30, 31] . In a study including HIV-infected women, MSM, and MSW, Beachler et al reported clearance rates, using 2 negative HPV results, of 31% and 55% for prevalent and incident HPV infection, both oncogenic and nononcogenic, over a mean of 24 months; women had clearance rates similar to the MSM [23] .
Our analysis shows that women with more than 1 concurrent HR-HPV type have a lower clearance rate than women with a single type, particularly in the anus, where the clearance rate of multitype HR-HPV infections was about half that of single HR-HPV type infections. The dynamics of multitype HPV infection in the cervix have been examined, with some studies reporting the acquisition of multiple HPV types exceeded that expected by chance [30] . If acquisition of multiple HPV types is biologically favored, then clearance of multitype infections could be more difficult. Furthermore, there seems to be an association between incident HPV infections between the 2 anatomical sites. Goodman et al found that among generally healthy women, presence of multiple HPV types in the cervix was associated with a 2.5-fold increased likelihood of subsequent anal infection [30] . These dynamics may have implications for vaccine effectiveness. Conceivably, the vaccine could increase clearance rates of HPV types by decreasing the number of concurrent HPV types in either the anus or cervix. The multifactorial mechanisms of HPV incidence and clearance have been studied by others [32, 33] . Most abnormal cytologies, including HSIL and ASC-H, had 9v HR-HPV types detected, either alone or with non-9v HR types, but 8% of abnormal anal and 12% of abnormal cervical cytologies had only non-9v HR-HPV types identified. It is not clear from these data what role, if any, these types may have in causing high-grade abnormalities leading to cancer; the HPV types covered by the current nonavalent vaccine have a higher likelihood of causing cytological abnormalities than other HR types [27] . Because infection with multiple, concurrent HPV types appears to decrease the likelihood of HPV clearance, the fact that a significant number of women had both 9v and non-9v HR types concurrently might lead to more persistent infection and a greater likelihood of developing abnormal anogenital cytology. Most importantly, this was noted among women with HSIL/ASC-H where the potential for disease progression is greatest [34] .
Our study had a number of limitations. We did not have an HIV-uninfected cohort of women for comparison, nor quantified amounts of HPV detected. Also, due to limited sample size, we were unable to evaluate risk factors for HPV acquisition in multivariable analyses. Furthermore, we did not have histology data to confirm the presence of abnormal cytology findings, and may have underestimated the number of abnormalities. We did not collect data on treatment of abnormal anal or cervical cytology. Women with cervical abnormalities were treated as per standards of care and those with anal abnormalities were monitored with repeat sampling. Strengths of our study include annual testing for 37 HPV types and relatively long follow-up, up to 5 years, to assess incidence and clearance.
In summary, we found that the prevalence of anal HR-HPV infection was higher than cervical and, for most HPV types, cleared more slowly. The HR-HPV types covered by the nonavalent HPV vaccine had similar clearance rates to HR-HPV types not included, and women infected with multiple anogenital HR-HPV types had lower rates of clearance than women infected with only 1 type. The majority of HR-HPV types we detected in abnormal anogenital cytologies were types included in the 9v vaccine, and because its use might impact the clearance rates of HR-HPV by decreasing the overall burden of anogenital HPV infection in HIV-infected women, these findings further support use of the nonavalent vaccine. 
